Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Amy Herr
University of California Berkeley, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zephyrus Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Committee determined that the PI’s interest in Zephyrus Biosciences,is related to the interest of the project and represents an FCOI in that those interests could directly and significantly affect the design, conduct or reporting of the PHS-funded research by bringing attention to the SFI's products/IP.
Measuring biophysical & protein signaling indicators of invasion potential in single-circulating tumor cells
Clinical relevance statement: Classification & study of CTCs as putative `metastasis initiating cells' (MICs) is stymied owing to the limited analytical tool an biased positive surface marker selection. With R21 support, this project will provide direct correlation of transendothelial migration phenotypes & metastasis-related protein signaling states in single CTCs, forming the basis for identification of metastasis-initiating CTCs based on biochemical properties alone in the future. Envisioned in our long-term goal, identification and molecular classification of metastasis-initiating CTCs by real-time blood draw will be an effective mean to predict metastasis and determine therapeutic interventions.
Filed on July 25, 2016.
Tell us what you know about Amy Herr's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Amy Herr filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Amy Herr | University of California Berkeley | Conflict of Interest | Zephyrus Biosciences | $0 - $4,999 |
| Amy Herr | University of California Berkeley | Conflict of Interest | Zephyrus Biosciences | Value cannot be readily determined |
| Amy Herr | University of California Berkeley | Conflict of Interest | Zephyrus Biosciences | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.